Nama Insights

Elanco Animal Health (ELAN)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Elanco Animal Health (ELAN) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $13.14B, a trailing price-to-earnings ratio of 23.1 and a free-cash-flow yield of 2.2%. Over the most recent reported fiscal year, revenue grew 6.2% and free cash flow per share fell 27.8%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Hold · 5.5/10
The sections balance. As of Nov 20, 2026.
Momentum
Middle · +6.2% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-21.6%
How far the last close sits under the highest price of the past five years.
Market cap$13.14B
Trailing P/E23.1
Price / book2.0
Price / sales2.5
FCF yield2.2%
Dividend yield—
Gross margin56.2%
Operating margin7.6%
Net margin-2.9%
Revenue growth (YoY)+6.2%
Revenue growth (3-yr annual)+2.2%
EPS growth (YoY)+4.4%
FCF/share growth (YoY)-27.8%
Beta1.7
ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers Specialty Generic

ELAN earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.17). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 6, 2026 $0.27 $0.20 +35.0% $1.26B
Q2 2026 Aug 5, 2026 $0.34 $0.27 +25.9% $1.37B
Q1 2026 May 6, 2026 $0.40 $0.34 +17.6% $1.37B
Q4 2025 Feb 24, 2026 $0.13 $0.12 +8.3% $1.14B

ELAN analyst price target

Median target $32.00 from 13 analysts, ranging $25.00 – $35.00.

Drug Manufacturers Specialty Generic peers

TickerCompanyMarket capP/E
TAK Takeda Pharmaceutical $68.40B 43.7
TEVA Teva Pharmaceutical Industries $44.97B 16.3
HLN Haleon $39.67B 21.1
ZTS Zoetis $32.83B 12.2
UTHR United Therapeutics $23.81B 21.1
VTRS Viatris $22.79B 7.8
NBIX Neurocrine Biosciences $15.85B 15.7
RDY Dr. Reddy's Laboratories $12.36B 20.3
Explore live ELAN data on Nama Insights →

Recent Congressional trades

Elanco Animal Health trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Valerie Hoyle House Sell $1,001 - $15,000 Oct 10, 2025

ELAN FAQ

Is ELAN a buy?
Nama's AI scorecard currently rates Elanco Animal Health Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ELAN's P/E ratio?
Elanco Animal Health trades at a trailing price-to-earnings ratio of 23.1.
When does ELAN report earnings?
Elanco Animal Health's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.17.
What is the ELAN price target?
The median analyst price target from 13 analysts is $32.00, with a range of $25.00 – $35.00.
Is ELAN Shariah compliant?
Nama's AAOIFI-style screen reads Elanco Animal Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.